Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon National Health Strategy-Vision 2030



Lebanon National Health Strategy – Vision 2030- Two Year Review
Lebanon National Health Strategy – Vision 2030- One Year Review

Introduction

In January 2023, the Ministry of Public Health (MoPH) launched its National Health Strategy: Vision 2030. Vision 2030 set out the framework for a sustained and modernized recovery of the health sector and intended to address the challenges of leading a burned-out health system. Through this strategy, and under the leadership of the MoPH, the different partners of the health sector joined efforts to respond to the escalating unmet health needs and participate in building a stronger, more resilient health system.

Over the past year, the National Health Strategy has made significant strides in enhancing the overall well-being of the population. The multifaceted approach has addressed key issues such as human resources shortage, challenged healthcare accessibility, and the massive gaps in health financing. Despite the multiple predicaments in the country, including the ongoing war and hostilities; the economic collapse and financial meltdown; the extended refugee crisis with its associated increased demand for scarce health resources; and disease outbreaks such as cholera; the health sector remained steady, and determined in achieving progress across the objectives outlined in the National Health Strategy. The National Health Strategy’s commitment to fostering advanced governance and financing mechanisms, investing in essential public health functions, strengthening primary healthcare, capacitating human resources, and embracing digital health technologies is expected to result in an advanced, more equitable, more inclusive, and more sustainable healthcare delivery.(Read More...)
 
Lebanon National Health Strategy: Vision 2030
 
Executive Summary

Lebanon is passing through one of the most severe and complex crises in its recent history, caused by the interplay of political turbulence, socioeconomic meltdown, and the lingering COVID-19 pandemic. Regionally, conflict and instability continue to result in the influx of refugees, which constitute now around one third of the Lebanese population.

The intertwined crises Lebanon has been suffering from unmasked the effects of pre-existing health system inefficiencies, including the predominance of tertiary care over preventive and primary care; a weakened public health sector; a pluralistic financing system; and a supply-induced demand with unsustainable and unrealistic expectations. The synergistic effects of these crises amplified the malfunctioning of a disrupted health system, rendering a system notorious for its resilience at the verge of a breakdown. As a result, the ability to respond to the increased needs of a growing population was deterred. Equitable access to care was exceptionally difficult for people with vulnerabilities. Worsening in health outcomes was noted at many fronts: life expectancy, maternal mortality, under 5 mortality, and childhood vaccination. Previously forgotten diseases such as diphtheria, tetanus, and most recently cholera re-emerged, and the health gains of previous years have started to fade away.

The multifaceted crisis has also severely impacted access to and utilization of healthcare services. The percentage of households with difficulty accessing health care rose from 25% to 36% within around 4 months during the year 2020. Hospitalizations, particularly for surgeries, diminished by 30% in 2021, and the average monthly hospitalization days decreased by 25%. The cost of treatments, medical consultations, or transportation to health facilities have become prohibitive to many, resulting in delayed presentation of patients for medical attention, who at many times presented with decompensated or non-salvageable conditions. Duly, challenged access to specialized healthcare was coupled with an exponential increased demand on the services provided by the Primary Health Care Network. With crisis, an opportunity has emerged for repositioning primary health care as a gateway for affordable, quality promotive, preventive, and primary health services, and for moving closer towards achieving Universal Health Coverage.

The recent drain of human resources particularly those with high competencies and specialization has become an increasing concern, with more than 20% of nurses and around 40% of doctors having already left the country. Additionally, the layoffs, salary cuts and closures of pharmacies and the reduced activities of hospitals which accompanied the economic crisis, deleteriously affected the healthcare workforce. This shortage in qualified human resources endangered the quality and availability of health care services.

The pharmaceutical sector was also hit hard by the crisis. In 2020, the government’s policy of relying on external sources for medications and medical supplies, coupled the economic crisis, led to drops in imports, resulting in severe market shortages. This has paved the way to hoarding, smuggling, black market practices, and the entry of illegal, low-quality drugs and supplies into the country.(Read More...)


ِAnnexes:
    ...
    178
ATC Name B/G Ingredients Dosage Form Price
N03AX14 ZITERA G Levetiracetam - 500mg 500mg Tablet, film coated 2,203,902 L.L
N03AX14 ZITERA G Levetiracetam - 1,000mg 1,000mg Tablet, film coated 3,225,222 L.L
J01FA10 ZITHROFORTE G Azithromycin (dihydrate) - 500mg 500mg Tablet, film coated 485,127 L.L
J01FA10 ZITHROMAX B Azithromycin (dihydrate) - 300mg/7.5ml 300mg/7.5ml Powder for suspension 489,159 L.L
J01FA10 ZITHROMAX B Azithromycin (dihydrate) - 250mg 250mg Capsule 591,291 L.L
C10AA01 ZOCOR B Simvastatin - 10mg 10mg Tablet 881,817 L.L
C10AA01 ZOCOR B Simvastatin - 20mg 20mg Tablet 976,526 L.L
C10AA01 ZOCOR B Simvastatin - 40mg 40mg Tablet 1,435,992 L.L
A04AA01 ZOFRAN B Ondansetron (HCl dihydrate) - 8mg 8mg Tablet, film coated 6,061,174 L.L
A04AA01 ZOFRAN INJECTION B Ondansetron (HCl dihydrate) - 4mg/2ml 4mg/2ml Injectable solution 6,971,989 L.L
A04AA01 ZOFRAN INJECTION B Ondansetron (HCl dihydrate) - 8mg/4ml 8mg/4ml Injectable solution 9,338,600 L.L
L02AE03 ZOLADEX DEPOT B Goserelin (acetate) - 3.6mg 3.6mg Injectable suspension 8,820,074 L.L
L02AE03 ZOLADEX LA B Goserelin (acetate) - 10.8mg 10.8mg Injectable suspension 35,121,328 L.L
L02AE03 ZOLADEX LA B Goserelin (acetate) - 10.8mg 10.8mg Injectable suspension L.L
N05AH03 ZOLAPINE G Olanzapine - 5mg 5mg Tablet, orodispersible 1,186,165 L.L
N05AH03 ZOLAPINE G Olanzapine - 10mg 10mg Tablet, orodispersible 2,106,249 L.L
M05BA08 ZOLEDRA G Zoledronic acid - 4mg 4mg Injectable powder for solution 6,368,470 L.L
M05BA08 ZOLEDRO-DENK G Zoledronic acid - 4mg/5ml 4mg/5ml Injectable concentrate for solution 4,388,990 L.L
M05BA08 ZOLEDRONIC ACID ACCORD G Zoledronic acid - 4mg/5ml 4mg/5ml Injectable concentrate for solution 7,028,741 L.L
M05BA08 ZOLEDRONIC ACID HIKMA G Zoledronic acid (monohydrate) - 4mg/5ml 4mg/5ml Injectable concentrate for solution 9,098,466 L.L
R06AE09 ZOLICIN G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 228,453 L.L
N02CC03 ZOLMITRIPTAN ARROW GENERIGUES G Zolmitriptan - 2.5mg 2.5mg Tablet, film coated 1,726,838 L.L
N02CC03 ZOLMITRIPTAN ARROW GENERIGUES G Zolmitriptan - 2.5mg 2.5mg Tablet, film coated 857,372 L.L
N02CC03 ZOLMITRIPTAN BIOGARAN G Zolmitriptan - 2.5mg 2.5mg Tablet, orodispersible 921,876 L.L
N06AB06 ZOLOFT B Sertraline HCl - 50mg 50mg Tablet, scored 596,666 L.L
N06AB06 ZOLOFT B Sertraline HCl - 50mg 50mg Tablet, scored 596,666 L.L
J01FA10 ZOMAX G Azithromycin (dihydrate) - 200mg/5ml 200mg/5ml Powder for suspension 258,018 L.L
J01FA10 ZOMAX G Azithromycin (dihydrate) - 250mg 250mg Capsule 360,150 L.L
M05BA08 ZOMETA B Zoledronic acid (monohydrate) - 4mg/5ml 4mg/5ml Injectable concentrated solution 13,697,658 L.L
A04AA01 ZONETRON ODT G Ondansetron - 8mg 8mg Tablet, orodispersible 998,283 L.L
    ...
    178
Sitemap
© Copyrights reserved to Ministry of Public Health 2025